{"success":true,"data":{"pressRelease":{"id":"131457","rtpr_id":"nGNXJFNDX","ticker":"AVR","exchange":"NASDAQ","all_tickers":["AVR"],"title":"Anteris to Present at September Healthcare Investor Conferences","author":"Globe Newswire","published_at":"2026-08-31T18:45:00.100Z","article_body":"MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris\nTechnologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR,\nASX: AVR) a global healthcare company committed to designing, developing, and\ncommercializing cutting-edge medical devices to restore healthy heart\nfunction, is pleased to advise that Vice Chairman and Chief Executive Officer,\nWayne Paterson, will be presenting at the Cantor Global Healthcare Conference,\nthe Wells Fargo 21(st) Annual Healthcare Conference and the Morgan Stanley\n24(th) Annual Global Healthcare Conference.\n\nThe details of each conference are as follows:\n\nCantor Global Healthcare Conference\n\n Date:       Wednesday, September 9, 2026 (US time)                        \n Format:     Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings  \n Time:       11:30AM (US EST)                                              \n Room:       Track 1 – Metropolitan Room                                   \n Location :  Waldorf Astoria Hotel, New York                               \n\nWells Fargo Healthcare Conference\n\n Date:      Thursday, September 10, 2026 (US time)                         \n Format:    Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings  \n Time:      9:30AM (US EST)                                                \n Room:      Track 1 – Picasso 6                                            \n Location:  Encore Boston Harbor Hotel, Boston                             \n\nMorgan Stanley Healthcare Conference\n\n Date:      Monday, September 14, 2026 (US time)               \n Format:    Fireside chat with Morgan Stanley Healthcare Team  \n Time:      9:15AM (US EST)                                    \n Room:      Soho Complex 7th Floor                             \n Location:  Sheraton Times Square Hotel, New York              \n\nAbout Anteris\n\nAnteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global\nhealthcare company committed to designing, developing, and commercializing\ncutting-edge medical devices to restore healthy heart function. Founded in\nAustralia, with a significant presence in Minneapolis, USA, Anteris is a\nscience-driven company with an experienced team of multidisciplinary\nprofessionals delivering restorative solutions to structural heart disease\npatients.\n\nAnteris’ lead product, the DurAVR(®) Transcatheter Heart Valve (THV), was\ndesigned in collaboration with the world’s leading interventional\ncardiologists and cardiac surgeons to treat aortic stenosis – a potentially\nlife-threatening condition resulting from the narrowing of the aortic valve.\nThe balloon-expandable DurAVR(®) THV is the first biomimetic valve, which is\nshaped to mimic the performance of a healthy human aortic valve and aims to\nreplicate normal aortic blood flow. DurAVR(® )THV is made using a single\npiece of molded ADAPT(®) tissue, Anteris’ patented anti-calcification\ntissue technology. ADAPT(®) tissue, which is FDA-cleared, has been used\nclinically for over 10 years and distributed for use in over 55,000 patients\nworldwide. The DurAVR(®) THV System is comprised of the DurAVR(®) valve, the\nADAPT(®) tissue, and the balloon-expandable ComASUR(®) Delivery System.\n\nForward-Looking Statements\n\nThis announcement contains forward-looking statements. Forward-looking\nstatements include all statements that are not historical facts.\nForward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “budget,” “target,” “aim,” “strategy,”\n“plan,” “guidance,” “outlook,” “may,” “should,”\n“could,” “will,” “would,” “will be,” “will continue,”\n“will likely result” and similar expressions, although not all\nforward-looking statements contain these identifying words. These\nforward-looking statements are subject to a number of risks, uncertainties,\nand assumptions, including those described under “Risk Factors” in\nAnteris’ Annual Report on Form 10-K for the fiscal period ended December 31,\n2025 that was filed with the Securities and Exchange Commission and ASX.\nActual future events may vary from these forward-looking statements and\nreaders are cautioned not to put undue reliance on forward-looking statements.\nOther than as required by law, Anteris gives no representation or guarantee\nthat the occurrence of any of the events or circumstances expressed or implied\nin these statements will occur. In addition, except as required by law,\nAnteris does not assume any obligation to update any of these forward-looking\nstatements to conform these statements to actual results or revised\nexpectations.\n\nFor more information:\n\n Global Investor Relations investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200      Investor Relations (US) mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269  \n                                                                                                                                                                                                                                                                          \n Website X LinkedIn                                                    www.anteristech.com @AnterisTech https://www.linkedin.com/company/anteristech                                                                                                                      \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXJFNDX","title":"Anteris to Present at September Healthcare Investor Conferences","author":"Globe Newswire","ticker":"AVR","created":"2026-08-31T18:45:00.100Z","tickers":["AVR"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris\nTechnologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR,\nASX: AVR) a global healthcare company committed to designing, developing, and\ncommercializing cutting-edge medical devices to restore healthy heart\nfunction, is pleased to advise that Vice Chairman and Chief Executive Officer,\nWayne Paterson, will be presenting at the Cantor Global Healthcare Conference,\nthe Wells Fargo 21(st) Annual Healthcare Conference and the Morgan Stanley\n24(th) Annual Global Healthcare Conference.\n\nThe details of each conference are as follows:\n\nCantor Global Healthcare Conference\n\n Date:       Wednesday, September 9, 2026 (US time)                        \n Format:     Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings  \n Time:       11:30AM (US EST)                                              \n Room:       Track 1 – Metropolitan Room                                   \n Location :  Waldorf Astoria Hotel, New York                               \n\nWells Fargo Healthcare Conference\n\n Date:      Thursday, September 10, 2026 (US time)                         \n Format:    Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings  \n Time:      9:30AM (US EST)                                                \n Room:      Track 1 – Picasso 6                                            \n Location:  Encore Boston Harbor Hotel, Boston                             \n\nMorgan Stanley Healthcare Conference\n\n Date:      Monday, September 14, 2026 (US time)               \n Format:    Fireside chat with Morgan Stanley Healthcare Team  \n Time:      9:15AM (US EST)                                    \n Room:      Soho Complex 7th Floor                             \n Location:  Sheraton Times Square Hotel, New York              \n\nAbout Anteris\n\nAnteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global\nhealthcare company committed to designing, developing, and commercializing\ncutting-edge medical devices to restore healthy heart function. Founded in\nAustralia, with a significant presence in Minneapolis, USA, Anteris is a\nscience-driven company with an experienced team of multidisciplinary\nprofessionals delivering restorative solutions to structural heart disease\npatients.\n\nAnteris’ lead product, the DurAVR(®) Transcatheter Heart Valve (THV), was\ndesigned in collaboration with the world’s leading interventional\ncardiologists and cardiac surgeons to treat aortic stenosis – a potentially\nlife-threatening condition resulting from the narrowing of the aortic valve.\nThe balloon-expandable DurAVR(®) THV is the first biomimetic valve, which is\nshaped to mimic the performance of a healthy human aortic valve and aims to\nreplicate normal aortic blood flow. DurAVR(® )THV is made using a single\npiece of molded ADAPT(®) tissue, Anteris’ patented anti-calcification\ntissue technology. ADAPT(®) tissue, which is FDA-cleared, has been used\nclinically for over 10 years and distributed for use in over 55,000 patients\nworldwide. The DurAVR(®) THV System is comprised of the DurAVR(®) valve, the\nADAPT(®) tissue, and the balloon-expandable ComASUR(®) Delivery System.\n\nForward-Looking Statements\n\nThis announcement contains forward-looking statements. Forward-looking\nstatements include all statements that are not historical facts.\nForward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “budget,” “target,” “aim,” “strategy,”\n“plan,” “guidance,” “outlook,” “may,” “should,”\n“could,” “will,” “would,” “will be,” “will continue,”\n“will likely result” and similar expressions, although not all\nforward-looking statements contain these identifying words. These\nforward-looking statements are subject to a number of risks, uncertainties,\nand assumptions, including those described under “Risk Factors” in\nAnteris’ Annual Report on Form 10-K for the fiscal period ended December 31,\n2025 that was filed with the Securities and Exchange Commission and ASX.\nActual future events may vary from these forward-looking statements and\nreaders are cautioned not to put undue reliance on forward-looking statements.\nOther than as required by law, Anteris gives no representation or guarantee\nthat the occurrence of any of the events or circumstances expressed or implied\nin these statements will occur. In addition, except as required by law,\nAnteris does not assume any obligation to update any of these forward-looking\nstatements to conform these statements to actual results or revised\nexpectations.\n\nFor more information:\n\n Global Investor Relations investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200      Investor Relations (US) mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269  \n                                                                                                                                                                                                                                                                          \n Website X LinkedIn                                                    www.anteristech.com @AnterisTech https://www.linkedin.com/company/anteristech                                                                                                                      \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-31T18:45:00.146118583Z","server_sent_at_ms":1788201900146},"received_at":"2026-08-31T18:45:00.205Z","source_url":null},"analysis":{"id":"120368","press_release_id":"131457","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Anteris Technologies announced that CEO Wayne Paterson is scheduled to present at three upcoming investor conferences: the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Healthcare Conference.\n\nThe events will feature fireside chats with analysts and one-on-one meetings, taking place in New York and Boston between September 9 and September 14, 2026.\n\nAnteris focuses on structural heart disease solutions, led by its DurAVR Transcatheter Heart Valve which utilizes the company's patented ADAPT tissue technology.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Management visibility on the conference circuit next month."},"keyFigures":null,"namedEntities":{"people":[{"name":"Wayne Paterson","role":"Vice Chairman and CEO"},{"name":"Gabie Ingoglia","role":"Analyst"},{"name":"Larry Biegelsen","role":"Analyst"}],"products":["DurAVR Transcatheter Heart Valve (THV)","ADAPT tissue","ComASUR Delivery System"],"companies":[{"name":"Anteris Technologies Global Corp.","ticker":"AVR"},{"name":"Blueprint Life Science Group","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of management participation at investor conferences. No material corporate developments, financial results, or clinical data released."},"tickerRelevance":{"others":[],"primary":"AVR"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/micro-cap","eventGravity":"conference_attendance","sectorWeight":"healthcare_devices"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Anteris Technologies announced that CEO Wayne Paterson is scheduled to present at three upcoming investor conferences: the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, and Morgan Stanley Healthcare Conference.\n\nThe events will feature fireside chats with analysts and one-on-one meetings, taking place in New York and Boston between September 9 and September 14, 2026.\n\nAnteris focuses on structural heart disease solutions, led by its DurAVR Transcatheter Heart Valve which utilizes the company's patented ADAPT tissue technology.","key_figures":null,"named_entities":{"people":[{"name":"Wayne Paterson","role":"Vice Chairman and CEO"},{"name":"Gabie Ingoglia","role":"Analyst"},{"name":"Larry Biegelsen","role":"Analyst"}],"products":["DurAVR Transcatheter Heart Valve (THV)","ADAPT tissue","ComASUR Delivery System"],"companies":[{"name":"Anteris Technologies Global Corp.","ticker":"AVR"},{"name":"Blueprint Life Science Group","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T18:47:09.028Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small/micro-cap","eventGravity":"conference_attendance","sectorWeight":"healthcare_devices"}},"durationMs":128813,"modelName":"glm-4.7"}}